f it list
TECVAYLI® (teclistamab-cqyv) demonstrates potential as frontline combination therapy for patients with newly diagnosed multiple myelomaNone
Abercrombie & Fitch director Suzanne Coulter sells $459,200 in stockExploratory long-term follow-up analysis of the phase III POLARIX study indicated a positive trend in overall survival in favour of Polivy in combination with R-CHP for people with first-line diffuse large B-cell lymphoma (DLBCL) 1 Patients treated with Polivy in combination with R-CHP required fewer subsequent treatments, potentially reducing burdens on patients and healthcare systems 1 These encouraging five-year results continue to highlight the potential of this Polivy combination to improve outcomes in first-line DLBCL, an area that previously had little advancement in nearly two decades Basel, 8 December 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today data from a five-year follow-up of the pivotal phase III POLARIX study evaluating Polivy® (polatuzumab vedotin) in combination with MabThera®/Rituxan® (rituximab), cyclophosphamide, doxorubicin and prednisone (R-CHP) in people with untreated diffuse large B-cell lymphoma (DLBCL). Data were presented in an oral session at the 66 th American Society of Hematology (ASH) Annual Meeting and Exposition, 7-10 December 2024 in San Diego, US. This latest analysis conducted after a median follow-up of 60.9 months, includes descriptive data on primary and secondary endpoints, as well as safety results. 1 “POLARIX was the first trial to elevate treatment standards for frontline diffuse large B-cell lymphoma in 20 years and we are additionally encouraged by the five-year follow-up results,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “More than 38,000 people worldwide have been treated with Polivy in combination with R-CHP and these data continue to underscore its potential to improve outcomes for people diagnosed with this aggressive lymphoma.” Follow-up exploratory analysis after five-years indicated a positive trend in overall survival (OS) in the intent-to-treat (ITT) population in favour of Polivy in combination with R-CHP compared to MabThera/Rituxan plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP). Results showed a trend in reduction in the risk of death (HR 0.85; 95% CI: 0.63–1.15) for people with previously untreated DLBCL with the Polivy combination, an improvement on the three-year follow-up data (HR 0.94; 95% CI: 0.67–1.33). The five-year analysis of POLARIX indicates that the full difference in OS between treatment arms has yet to be observed and an additional two years of follow-up will continue. 1 “Diffuse large B-cell lymphoma is a notoriously challenging cancer to treat, however, Polivy in combination with R-CHP has shown to be a critical advance for patients by helping to reduce relapse and disease progression,” said Gilles Salles, MD, PhD, Chief of Lymphoma Service, Division of Hematological Malignancies, Memorial Sloan Kettering Cancer Center, US. “The survival trend seen in this follow-up analysis reinforces the potential impact of frontline treatment with Polivy in combination with R-CHP and its role as a standard of care therapy.” In addition to the positive trend in OS, an observational analysis suggested nearly 25% fewer follow-up treatments such as radiation, systemic chemotherapy and CAR-T cell therapy were needed in patients receiving Polivy in combination with R-CHP compared to those treated with R-CHOP (38.3% vs 61.7%). 1 Based on findings from a previous economic analysis which found that total healthcare costs increased with each additional line of treatment in relapsed or refractory DLBCL, a reduction in the number of subsequent therapies could potentially alleviate some of the burdens associated with relapse and disease progression. 2 At five years of follow-up, benefits in progression-free survival and disease-free survival with Polivy in combination with R-CHP were maintained, consistent with the three-year follow-up data, reinforcing the potential of Polivy in combination with R-CHP to provide durable and lasting remissions. The latest follow-up data also showed a numerical reduction in death related to patients’ lymphoma in those treated with Polivy in combination with R-CHP compared to those treated with R-CHOP (9.0% vs 11.4%). The safety profile remains consistent with the known profiles of the individual study medicines with no new safety signals observed, reinforcing the positive benefit-risk profile of this Polivy combination. 1 Results from an expanded cohort of 1,000 patients including global and Chinese patients demonstrated comparability to the global ITT population. 1 Polivy in combination with R-CHP is currently approved for the treatment of first-line (1L) DLBCL in more than 90 countries worldwide including the US, countries throughout the EU, the UK, Japan, Canada and China. Roche continues to work with health authorities around the world to bring this treatment regimen to even more patients. Roche aims to offer various treatment options for DLBCL that meet the diverse needs of patients and healthcare systems. In an effort to elevate treatment standards even further, Roche is exploring Polivy in combination with other molecules including its bispecific antibodies. Studies include the phase III SUNMO trial evaluating the efficacy and safety of subcutaneously administered Lunsumio® (mosunetuzumab) in combination with intravenous (IV) Polivy versus IV MabThera/Rituxan plus gemcitabine and oxaliplatin (R-GemOx) in second-line or later DLBCL, and the phase III SKYGLO trial investigating the efficacy of Polivy in combination with R-CHP and Columvi® (glofitamab) versus Polivy in combination with R-CHP in 1L DLBCL. About the POLARIX study POLARIX [ NCT03274492 ] is an international phase III, randomised, double-blind, placebo-controlled study evaluating the efficacy, safety and pharmacokinetics of Polivy® (polatuzumab vedotin) plus MabThera®/Rituxan® (rituximab), cyclophosphamide, doxorubicin, and prednisone (R-CHP) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) in people with previously untreated diffuse large B-cell lymphoma (DLBCL). Eight-hundred and seventy-nine patients were randomised 1:1 to receive either Polivy plus R-CHP plus a vincristine placebo for six cycles, followed by MabThera/Rituxan for two cycles; or R-CHOP plus a Polivy placebo for six cycles, followed by two cycles of MabThera/Rituxan. The primary outcome measure is progression-free survival (PFS) as assessed by the investigator using the Lugano Response Criteria for malignant lymphoma. PFS is a clinically meaningful disease-related outcome for patients with previously untreated DLBCL as it represents the goal of first-line therapy: decreasing the risk of disease worsening. Overall survival is a secondary endpoint in the POLARIX study. About diffuse large B-cell lymphoma (DLBCL) DLBCL is the most common form of non-Hodgkin lymphoma (NHL), accounting for about one in three cases of NHL. 3 DLBCL is an aggressive (fast-growing) type of NHL. While it is generally responsive to treatment in the frontline, as many as 40% of people will relapse or have refractory disease, at which time salvage therapy options are limited and survival is short. 4,5 Improving treatments earlier in the course of the disease and providing much needed alternative options could help to improve long-term outcomes. Approximately 160,000 people worldwide are estimated to be diagnosed with DLBCL each year. 1,6 About Polivy® (polatuzumab vedotin) Polivy is a first-in-class anti-CD79b antibody-drug conjugate (ADC). The CD79b protein is expressed specifically in the majority of B-cells, an immune cell impacted in some types of non-Hodgkin lymphoma (NHL), making it a promising target for the development of new therapies. Polivy binds to cancer cells such as CD79b and destroys these B-cells through the delivery of an anti-cancer agent, which is thought to minimise the effects on normal cells. Polivy is being developed by Roche using Pfizer ADC technology and is currently being investigated for the treatment of several types of NHL. About Roche in haematology Roche has been developing medicines for people with malignant and non-malignant blood diseases for more than 25 years; our experience and knowledge in this therapeutic area runs deep. Today, we are investing more than ever in our effort to bring innovative treatment options to patients across a wide range of haematologic diseases. Our approved medicines include MabThera/Rituxan, Gazyva®/Gazyvaro® (obinutuzumab), Polivy, Venclexta®/Venclyxto® (venetoclax) in collaboration with AbbVie, Hemlibra® (emicizumab), PiaSky® (crovalimab), Lunsumio® (mosunetuzumab) and Columvi® (glofitamab). Our pipeline of investigational haematology medicines includes T-cell engaging bispecific antibody cevostamab, targeting both FcRH5 and CD3 and Tecentriq® (atezolizumab). Our scientific expertise, combined with the breadth of our portfolio and pipeline, also provides a unique opportunity to develop combination regimens that aim to improve the lives of patients even further. About Roche Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice. For over 125 years, sustainability has been an integral part of Roche’s business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com . All trademarks used or mentioned in this release are protected by law. References [1] Gilles S, et al. Five-Year Analysis of the POLARIX Study: Prolonged Follow-up Confirms Positive Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) on Outcomes. Presented at: ASH Annual Meeting and Exposition; 2024 Dec 7-10; San Diego, CA, USA. Abstract #469. [2] Gatwood J, et al. Total cost of care in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). Presented at: ASH Annual Meeting and Exposition; 2022, Dec 10-13. Abstract #3527 [3] Cancer.Net. Lymphoma - Non-Hodgkin: Subtypes. [Internet; cited December 2024]. Available from: https://www.cancer.net/cancer-types/lymphoma-non-hodgkin/subtypes [4] Sehn LH, et al. Diffuse Large B-Cell Lymphoma. N Engl J Med. 2021;384(9):842-858. [5] Maurer MJ, et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol. 2014;32:1066-73. [6] World Health Organization. Numbers derived from GLOBOCAN 2022. Non-Hodgkin Lymphoma Factsheet [Internet; cited December 2024]. Available from: https://gco.iarc.who.int/media/globocan/factsheets/cancers/34-non-hodgkin-lymphoma-fact-sheet.pd . Dr. Salles has financial interests related to Roche and Genentech. Roche Global Media Relations Phone: +41 61 688 8888 / e-mail: media.relations@roche.com Roche Investor Relations Investor Relations North America Attachment 08122024_POLARIX 5-year data_en
Kendrick Lamar surprises with new album 'GNX' LOS ANGELES (AP) — Kendrick Lamar gave music listeners an early holiday present with a new album. The Grammy winner released his sixth studio album “GNX” on Friday. The 12-track project is the rapper’s first release since 2022’s “Mr. Morale & The Big Steppers.” Lamar’s new album comes just months after his rap battle with Drake. The rap megastar will headline February's Apple Music Super Bowl Halftime Show in New Orleans. The 37-year-old has experienced massive success since his debut album “good kid, m.A.A.d city” in 2012. Since then, he’s accumulated 17 Grammy wins and became the first non-classical, non-jazz musician to win a Pulitzer Prize. NBA memo to players urges increased vigilance regarding home security following break-ins MIAMI (AP) — The NBA is urging its players to take additional precautions to secure their homes following reports of recent high-profile burglaries of dwellings owned by Milwaukee Bucks forward Bobby Portis and Kansas City Chiefs teammates Patrick Mahomes and Travis Kelce. In a memo sent to team officials, a copy of which was obtained by The Associated Press, the NBA revealed that the FBI has connected some burglaries to “transnational South American Theft Groups” that are “reportedly well-organized, sophisticated rings that incorporate advanced techniques and technologies, including pre-surveillance, drones, and signal jamming devices.” Ancient meets modern as a new subway in Greece showcases archaeological treasures THESSALONIKI, Greece (AP) — Thessaloniki, Greece’s second-largest city, is opening a new subway system, blending ancient archaeological treasures with modern transit technology like driverless trains and platform screen doors. The project, which began in 2003, uncovered over 300,000 artifacts, including a Roman-era thoroughfare and Byzantine relics, many of which are now displayed in its 13 stations. Despite delays caused by preserving these findings, the inaugural line has been completed, with a second line set to open next year. Conor McGregor must pay $250K to woman who says he raped her, civil jury rules LONDON (AP) — A civil jury in Ireland has awarded more than $250,000 to a woman who says she was raped by mixed martial arts fighter Conor McGregor in a Dublin hotel penthouse after a night of heavy partying. The jury on Friday awarded Nikita Hand in her lawsuit that claimed McGregor “brutally raped and battered” her in 2018. The lawsuit says the assault left her heavily bruised and suffering from post-traumatic stress disorder. McGregor testified that he never forced her to do anything and that Hand fabricated her allegations after the two had consensual sex. McGregor says he will appeal the verdict. At least 19 people are sick in Minnesota from ground beef tied to E. coli recall U.S. health officials say at least 19 people in Minnesota have been sickened by E. coli poisoning tied to a national recall of more than 167,000 pounds of potentially tainted ground beef. Detroit-based Wolverine Packing Co. recalled the meat this week after Minnesota state agriculture officials reported multiple illnesses and found that a sample of the product tested positive for E. coli O157:H7, which can cause life-threatening infections. Symptoms of E. coli poisoning include fever, vomiting, diarrhea and signs of dehydration. Actor Jonathan Majors’ ex-girlfriend drops assault and defamation lawsuit against once-rising star NEW YORK (AP) — Jonathan Majors’ ex-girlfriend has dropped her assault and defamation lawsuit against the once-rising Hollywood star after reaching a settlement. Lawyers for Majors and Grace Jabbari agreed to dismiss the case with prejudice Thursday. Jabbari is a British dancer who had accused Majors of subjecting her to escalating incidents of physical and verbal abuse during their relationship. Representatives for Majors didn’t respond to emails seeking comment Friday. Jabbari’s lawyer said the suit was “favorably settled” and her client is moving on with “her head held high.” Majors was convicted of misdemeanor assault and harassment last December and sentenced to a yearlong counseling program. Hyundai, Kia recall over 208,000 electric vehicles to fix problem that can cause loss of power DETROIT (AP) — Hyundai and Kia are recalling over 208,000 electric vehicles to fix a pesky problem that can cause loss of drive power, increasing the risk of a crash. The recalls cover more than 145,000 Hyundai and Genesis vehicles including the 2022 through 2024 Ioniq 5, the 2023 through 2025 Ioniq 6, GV60 and GV70, and the 2023 and 2024 G80. Also included are nearly 63,000 Kia EV 6 vehicles from 2022 through 2024. The affiliated Korean automakers say in government documents that a transistor in a charging control unit can be damaged and stop charging the 12-volt battery. Dealers will inspect and replace the control unit and a fuse if needed. They also will update software. Christmas TV movies are in their Taylor Swift era, with two Swift-inspired films airing this year Two of the new holiday movies coming to TV this season have a Taylor Swift connection that her fans would have no problem decoding. “Christmas in the Spotlight” debuts Saturday on Lifetime. It stars Jessica Lord as the world’s biggest pop star and Laith Wallschleger, playing a pro football player, who meet and fall in love, not unlike Swift and her boyfriend, Kansas City Chiefs tight end Travis Kelce. On Nov. 30, Hallmark will air “Holiday Touchdown: A Chiefs Love Story.” Instead of a nod to Swift, it’s an ode to family traditions and bonding, like rooting for a sports team. Hallmark’s headquarters is also in Kansas City. Top football recruit Bryce Underwood changes commitment to Michigan instead of LSU, AP source says ANN ARBOR, Mich. (AP) — Top football recruit Bryce Underwood has flipped to Michigan after pledging to play at LSU. That's according to a person familiar with the situation who spoke to The Associated Press on condition of anonymity because they were not authorized to share the recruit’s plans to join the Wolverines. Underwood pinned a post on his Instagram account, showing a post in which On3.com reported that he has committed to Michigan. The 6-foot-3 quarterback played at Belleville High School about 15 miles east of Michigan's campus, and told LSU nearly a year ago he intended to enroll there. Emperor penguin released at sea 20 days after waddling onto Australian beach MELBOURNE, Australia (AP) — The only emperor penguin known to have swum from Antarctica to Australia has been released at sea 20 days after he waddled ashore on a popular tourist beach. The adult male was found on Nov. 1 on sand dunes in temperate southwest Australia about 2,200 miles north of the Antarctic coast. He was released Wednesday from a boat that traveled several hours from Western Australia state's most southerly city of Albany. His caregiver Carol Biddulph wasn't sure at first if the penguin would live. She said a mirror was important to his rehabilitation because they provide a sense of company. Biddulph said: “They’re social birds and he stands next to the mirror most of the time.”
No. 1 South Carolina Upset by No. 5 UCLA; Snaps Gamecocks' 43-Game Winning StreakSamsara Stock Tumbles As Revenue Guidance UnderwhelmsA year ago, Blackhawks prospect Colton Dach was on the verge of an NHL call-up. Then inconsistency and injuries disrupted his rhythm, forcing him to — in the words of Rockford coach Anders Sorensen — “start over a little bit” this season. After more ups and downs this fall, Sorensen, who always seems more critical of Dach than the Hawks’ other AHL prospects, sat down with him Tuesday morning for a serious chat. That night against Texas, Dach was denied on two golden scoring chances in the first period, which might have rattled him in the past . But he stuck with it and broke through with two goals less than a minute apart in the second period of Rockford’s eventual win. Sorensen described it as Dach’s “most complete game” of the season, a rare instance of praise. “I’m not going to lie: I was definitely a little bit frustrated when I couldn’t put one in [early on],” Dach said. “But when I scored that first one, I let it all out and calmed myself down, and we went to work after that. “I need to play with confidence. When I’m doing that, I’m moving my feet, getting into guys, being physical and winning a lot of stick battles. That’s something I’ve got to keep doing.” Dach entered Saturday with 11 points in 14 games, trailing only top prospect Frank Nazar for the team lead. “It’s [about] the work off the puck,” Sorensen said. “We’ve talked a lot about the first four strides in transition, whether it’s one way or the other — similar to Frank, although they’re different body types obviously. [Dach is working on] getting his feet going early to get to spots or get in on the forecheck. When he does that, he’s really effective.” In his pursuit of an NHL call-up, Dach is mostly competing against Nazar, Landon Slaggert and Cole Guttman . The race could get more crowded soon if Boston University junior Ryan Greene and Minnesota sophomore Oliver Moore sign entry-level contracts in March or April after their college seasons end. Dach needs to maintain this inkling of momentum to have a chance to break through. He needs his December 2024 performance to be just as impressive as his December 2023 performance — and his January 2025 performance to greatly exceed his January 2024 performance. Waivers looming When the Hawks signed goaltender Laurent Brossoit in the summer, they knew they could send Arvid Soderblom to Rockford without the risk of losing him on waivers. If Brossoit misses much more time, however, that no longer may be the case. Soderblom’s six appearances this season have him up to 56 career NHL appearances; once he gets to 60, he’ll require waivers. Considering how much Soderblom has increased his stock — he has a .926 save percentage compared to .879 last season — that’s a risk the Hawks would be reluctant to take. Instead, they would be stuck with a logjam of three NHL goalies. For now, it’s only an academic concern because Brossoit seemingly has made no progress toward a return after his meniscus surgery. Weird stats After their 3-2 overtime loss to the Flyers, the Hawks have gone five games with only one power-play opportunity in each game. That’s a franchise record and the longest such streak by any team since 2019. Forward Lukas Reichel , on the other hand, seems to love Philadelphia. He has three multipoint games since the start of last season, and two have happened in Philly. He scored the Hawks’ first goal and assisted on the second.CCAR_McKie 10 pass from Vasko (Hensley kick), 8:15. GAST_FG Rickman 28, 14:07. GAST_Brock 19 run (Rickman kick), 8:38. CCAR_Courtney 5 pass from Vasko (Hensley kick), 4:16. CCAR_FG Hensley 43, :01. CCAR_C.Washington 18 run (Hensley kick), 10:56. GAST_FG Rickman 30, 7:06. CCAR_McKie 31 pass from Vasko (Hensley kick), 2:44. GAST_Brock 1 run (pass failed), :25. CCAR_Vasko 10 run (Hensley kick), 9:50. CCAR_FG Hensley 23, 8:33. CCAR_Fletcher 39 interception return (Hensley kick), 7:13. GAST_Fleming 6 pass from Lowe (Hurst pass from Lowe), 4:36. A_12,606. RUSHING_Coastal Carolina, Washington 20-124, Vasko 13-68, Bennett 8-43, Price 5-26, Lloyd 3-10, Taylor 1-5, Duplessis 1-1, (Team) 2-(minus 2). Georgia St., Brock 14-71, Veilleux 11-62, Lowe 3-47, Dukes 2-11, Beasley 3-11. PASSING_Coastal Carolina, Vasko 13-17-1-200, (Team) 0-1-0-0, Duplessis 0-1-1-0, Kim 0-1-0-0. Georgia St., Veilleux 15-26-4-205, Lowe 2-6-0-21. RECEIVING_Coastal Carolina, McKie 5-81, Tucker 3-31, Karr 2-35, Duplessis 1-41, Berrong 1-7, Courtney 1-5. Georgia St., Hurst 8-131, Dukes 3-15, Riles 2-26, Fleming 2-18, Brock 1-21, Milton 1-15. MISSED FIELD GOALS_None.
Transforming Tech Education with Comprehensive Learning ToolsMinnesota looks to stop skid vs. Bethune-Cookman
None
Michigan, Ohio State fight broken up with police pepper spray after Wolverines stun Buckeyes 13-10Data Integration Market Adoption Trends and Forecast 2024-2031 11-30-2024 06:08 PM CET | IT, New Media & Software Press release from: SkyQuest Technology The Data Integration Market is experiencing rapid growth, fueled by advancements in hardware, software, and digital infrastructure. With services spanning cloud computing, cybersecurity, data analytics, and artificial intelligence, the market is at the forefront of digital transformation across industries. Emerging technologies such as 5G, blockchain, and IoT are unlocking unprecedented opportunities, driving innovation and expansion. Get a Free Sample Report With Table Of Contents: https://www.skyquestt.com/sample-request/data-integration-market Market Size and Growth: Global Data Integration Market size was valued at USD 13.87 billion in 2022 and is poised to grow from USD 15.74 billion in 2023 to USD 38.20 billion by 2031, at a CAGR of 13.5% during the forecast period (2024-2031). The most valuable investment indicators are insights into key market trends, making it easier for potential participants to make informed decisions. The research seeks to identify numerous growth opportunities that readers can consider and capitalize on by utilizing all the relevant information. By closely analyzing critical factors that influence growth, such as pricing, production, profit margins, and value chain dynamics, future market expansion can be predicted with greater precision. Key Market Players: IBM Corporation (United States) Oracle Corporation (United States) SAP SE (Germany) Microsoft Corporation (United States) Informatica (United States) Talend (United States) Cisco Systems, Inc. (United States) Dell Technologies Inc. (United States) Syncsort (United States) SAS Institute Inc. (United States) Actian Corporation (United States) Attunity Ltd. (Israel) Adeptia Inc. (United States) Denodo Technologies (United States) Liaison Technologies (United States) SnapLogic (United States) Region-wise Market Insights The regional analysis offers detailed breakdowns of revenue, sales, and market share for key geographies. This section includes future growth projections, pricing strategies, and other critical metrics. Regions covered in the report: North America: United States, Canada, Mexico Europe: Germany, France, UK, Russia, Italy Asia-Pacific: China, Japan, Korea, India, Southeast Asia South America: Brazil, Argentina, Colombia Middle East & Africa: Saudi Arabia, UAE, Egypt, Nigeria, South Africa For Personalized Insights, Speak with Our Experts: https://www.skyquestt.com/speak-with-analyst/data-integration-market Segments covered in the Data Integration Market include: Component Tools and Service Deployment Cloud and On Premises Data Integration Market Size and Scope The Data Integration market has shown significant growth in recent years, fueled by rising demand for power electronics across industries such as automotive, telecommunications, and renewable energy. This market is set to grow further as the global adoption of electric vehicles and renewable energy increases. Data Integration are highly valued for their superior thermal conductivity, electrical insulation, and mechanical strength, making them essential components in power modules and electronic devices. With ongoing technological and manufacturing advancements, the applications of Data Integration are expected to expand, encompassing a broader range of uses in the near future. For a Comprehensive Report on the Data Integration Market 2024, Visit: https://www.skyquestt.com/report/data-integration-market Frequently Asked Questions What are the key global trends influencing the market? Who are the top manufacturers, and what are their strategies? How is the market evolving across regions? What are the major challenges and opportunities in the Data Integration Market? About Us: SkyQuest is an IP-focused Research and Investment Bank and Technology Accelerator. We offer access to technologies, markets, and financing across sectors like Life Sciences, CleanTech, AgriTech, NanoTech, and Information & Communication Technology. We collaborate closely with innovators, entrepreneurs, companies, and investors to help them leverage external R&D sources and optimize the economic potential of their intellectual assets. Our expertise in innovation management and commercialization spans North America, Europe, ASEAN, and Asia Pacific. Contact: Mr. Jagraj Singh Skyquest Technology 1 Apache Way, Westford, Massachusetts 01886, USA (+1) 351-333-4748 Visit our website: Skyquest Technology This release was published on openPR.
AP News Summary at 1:32 p.m. EST“Therefore everyone who hears these words of mine and puts them into practice is like a wise man who built his house on the rock.” — Matthew 7:24 We are building a foundation in our life that will simply make us antifragile. Luke 2:52 tells us that Jesus grew physically, mentally, socially and spiritually. Let us examine what this means physically for this week and we will move on to the others next time. Like all of growth, the real key is consistency. We can not simply exercise once a year and call it good. We must develop a rhythm in our life that will enable us to exercise this habit on a regular basis. The same is true with our mental growth. In many circles, when I ask if they are reading anything interesting, they look back at me in confusion. After a moment they come to their senses and inform me that when their formal education ended so did their reading practice. After reading a biography about Teddy Roosevelt where it mentioned how voracious of a reader he was, I resolved to read an average of a book a week for the rest of my life. I have kept that commitment. Because of modern technology that would not have been readily available to the Rough Rider, I can also listen to audio books. Teddy died with a book under his pillow. He never wanted to quit learning. We have other ways that we can strengthen the foundation of our minds. We can do puzzles; we can have interesting discussions. The best discussions often happen after some intense research. At the Gospel Rescue Mission several years ago now, we had a challenging decision to make. There were at least two directions we could follow. Even working through the puzzle of the problem was strengthening us mentally. A couple of staff members were tasked with doing research on the one option and another was tasked with the second main option. At an assigned time, they came together and debated the options. It was an amazing exercise. We were engaging with opposing sides of an issue and having an exciting and stimulating conversation. I could almost feel my brain cells growing. It was an amazing experience. Maybe instead of simply arguing we should take time to have discussions like that on our divisive topics. The key here would be that we would have to argue contrary to our preconceived ideas. Today there is no excuse not to learn and expand our thinking. It is easier than ever to explore ideas from around the world. We can listen to podcasts, read more articles and interact in classroom settings. Expanding our minds give us options. More options will reduce our stress. Imagine you are engaging with a problem that is a three (on a scale of 1-10 with 1 being easy and 10 being difficult.) If you only have the mind capacity of a two. This problem will be challenging. However, if you develop your brain to a seven or eight, the problem will be of no great challenge. Finally, to develop your mind you need to engage with the Scriptures. Read them, meditate on them and seek to apply them. Make sure you take time to ask the Holy Spirit to help you to develop your mind. Rich Schaus is the executive director of Gospel Rescue Mission.
Americans certainly have a sweet tooth. We consume about 17 teaspoons of added sugar daily , about five more than our recommended allotment. We add sugar to almost everything, including beverages, snacks, and many processed and prepared foods. While our sugar intake isn't good for our waistlines, it is great for the bottom lines of companies that sell us all the sweet things we desire. Many of these companies make so much money satisfying our sugar cravings that they can lavishly pay dividends to their investors. Because of that, they can help satisfy an investor's craving for passive income. Here are two great sugar stocks to buy for a sweet stream of dividend income . Coca-Cola Coca-Cola ( KO 0.25% ) likely doesn't need much introduction to those with a sweet tooth. The global beverage giant sells sweetened sparkling soft drink brands Coca-Cola, Sprite, and Fanta. It also sells water, sports, coffee, tea, juice, value-added dairy, and plant-based beverage brands, many of which it sweetens. While Coca-Cola is working to reduce the sugar in its drinks through innovative new products, it's certainly a contributor to our high sugar intake. The company has been a sweet dividend stock over the years. It has increased its payment for 62 straight years, qualifying it as an elite Dividend King , a company with 50 or more years of annual dividend growth. The beverage giant most recently increased its dividend payment by 5.4%. It paid $8 billion in dividends last year and has dished out over $80 billion in cash to its shareholders since 2010. Coca-Cola's dividend currently yields roughly 3%. That's a sweet payout, considering the S&P 500 's dividend yield currently sits near a 20-year low of around 1.2%. The company should be able to continue building on its legacy and increasing its payout in the future. Coca-Cola expects to organically grow its revenue by 4% to 6% annually, which should drive 7% to 9% annual earnings-per-share growth over the long term. That should enable the beverage behemoth to continue satisfying its investors' cravings for a growing stream of passive dividend income. Hershey Hershey ( HSY -0.08% ) is the country's top confectioner. It's also the No. 2 player in the U.S. snacking industry. Its iconic confectionary brands include Hershey's, Reese's, Kisses, Kit Kat, Jolly Ranger, and Twizzlers. Hershey also sells salty snacks, like SkinnyPop, Pirate's Booty, and Dot's Homestyle Pretzels. The chocolatier pays a sweet dividend. Like Coca-Cola, its dividend currently yields more than 3%. The company has increased its payment for 15 straight years and has grown it at a more than 10% annual rate over the past decade. Hershey expects to continue growing in the future. It's targeting 2%-4% annual net sales growth and 6% to 8% adjusted earnings-per-share growth over the long term. The company is also investing in developing innovative new products to drive growth. It will also make acquisitions as opportunities arise. For example, it recently expanded its sweets portfolio by acquiring Sour Strips to bolster its presence in the fast-growing sour candy segment. The company's ability to develop new products and further its expansion through acquisition should enable it to continue increasing its delicious dividend. Satisfying income streams Coca-Cola and Hershey make a lot of money by feeding into our sugar addictions. That gives them the cash to pay lavish dividends. They have great records of growing their dividends, which seems likely to continue. Those features make them tasty stocks to buy for those seeking to collect some sweet passive income .AP Trending SummaryBrief at 4:39 p.m. EST
Shares of Uber Technologies ( UBER -9.60% ) fell 9.6% in today's trading. At first it may seem odd for Uber to be falling, as the company didn't make any major announcements today. However, a possible future competitor did, with big potential long-term implications. Waymo is coming to Miami On Thursday, autonomous ride-hailing company Waymo, which is majority owned by Alphabet ( GOOG -1.01% ) ( GOOGL -0.99% ) , announced it would be expanding to Miami in 2025, with the goal of offering autonomous rides by 2026. Waymo was founded in 2009 as one of Alphabet's "Other Bets," or "moonshot" projects that could one day turn into a big business. Waymo was then spun off into a separate subsidiary company in 2016, and has attracted outside funding to help Alphabet bring its technology to market. In fact, Waymo just raised another $5.6 billion from a group of major venture capital firms in late October. Deepwater Asset Management recently estimated that Alphabet still owns about 70% of the company today. With its own ride-hailing app, Waymo is already delivering autonomous rides in San Francisco, Los Angeles, and Phoenix. Therefore, Waymo could potentially become a big competitor to Uber, which dominates ride-hailing today. Yet the two companies have also partnered in the recent past. In September, Uber and Waymo announced they would jointly bring autonomous rides to Austin and Atlanta through the Uber app. As part of that partnership, Uber will provide fleet management services. However, Waymo identified another partner, Moove, for fleet management in Miami. So, perhaps Uber being cut out of the Miami announcement led to such a big sell-off today. Uber dominates ride-hailing today, but that could change Investors might have thought Uber would partner Waymo in each additional city Waymo enters. However, it looks as if Uber isn't the only game in town for fleet management. If Uber can leverage its dominant ride-hailing network effects in the age of autonomy , this sell-off could be an opportunity to buy. However, there's also a chance Uber may be disrupted by autonomy. In that case, all bets are off.
Ottawa police officer found not guilty of manslaughter testifies at Abdirahman Abdi inquestIndia slammed developed countries for causing the climate crisis during a landmark hearing at the International Court of Justice (ICJ) on Thursday, saying they exploited the global carbon budget, failed to honour climate finance promises and are now demanding that developing countries restrict their resource use. The court is examining what legal obligations countries have to address climate change and the consequences if they fail. Making submissions on behalf of India, Luther M. Rangreji, Joint Secretary in the Ministry of External Affairs (MEA), said, "If the contribution to degradation is unequal, the responsibility must also be unequal." India said developing nations were the hardest hit by climate change, despite contributing the least to it. "The developed world, which historically contributed the most, is ironically the best equipped with the technological and economic means to address this challenge," Mr. Rangreji said. He criticised rich countries for enjoying the benefits of fossil fuels while discouraging developing nations from using their own energy resources. "Countries which have reaped development benefits from exploiting fossil fuels demand developing countries to not utilise the national energy resources available to them," he said. India also slammed the lack of action on climate finance commitments. "The $100 billion pledged at the Copenhagen COP in 2009 by developed country parties and the doubling of the contribution to the Adaptation Fund have not yet been translated into any concrete actions," India noted. It called the new climate finance package for the Global South agreed at COP29 in Baku "too little, too distant" to meet the urgent needs of developing countries. India also reaffirmed its commitment to its climate targets under the Paris Agreement, but warned against overburdening its citizens. "There is a limit on how much we burden our citizens, even when India is pursuing Sustainable Development Goals for one-sixth of humanity," it said. The hearing is the result of years of campaigning by Pacific Island nations and Vanuatu, which led to a UN resolution asking the ICJ for an advisory opinion. Over the next two weeks, 98 countries, including small island nations and large emitters, will present their views. Though non-binding, the ICJ's opinion could set a moral and legal benchmark in the global fight against climate change. Published - December 06, 2024 03:42 am IST Copy link Email Facebook Twitter Telegram LinkedIn WhatsApp Reddit A push for more climate action Explained | Can countries be sued over climate change? international law / international court or tribunal / international relations / laws / climate change / United Nations (climate change)
Shield AI and Palantir Technologies Deepen Strategic Partnership and Announce Deployment of Warp SpeedNone
Oilers' Hyman can still crack Canada's 4 Nations Face-Off team: report